Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471386 | 0.84 | NPC1 (0.40) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL8473799 | 0.83 | NPC1 (0.39) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL8477439 | 0.82 | NPC1 (0.43) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL1468843 | 0.75 | NPC1 (0.41) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL6722438 | 0.73 | ATM (0.38) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL25344141 | 0.72 | NPC1 (0.35) | NPC1 | |
| SCHEMBL2786159 | 0.72 | ALDH1A1 (0.54) | NPC1SLC9A1ADRA1AADRA1BADRA1D | |
| SCHEMBL29674632 | 0.71 | NPC1 (0.46) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL24598999 | 0.71 | NPC1 (0.36) | NPC1DGAT1 | |
| SCHEMBL22632582 | 0.70 | NPC1 (0.46) | NPC1HTTMAPTDGAT1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409934-B2 | Cyclohexenyl nucleic acids analogs | IONIS PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20140073786-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8604192-B2 | Cyclohexenyl nucleic acids analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2361256-B1 | CYCLOHEXENYL NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2361256-A1 | CYCLOHEXENYL NUCLEIC ACID ANALOGS | Isis Pharmaceuticals, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172294-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | IONIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2010036696-A1 | CYCLOHEXENYL NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | NPC1 893/4885SLC9A1 1505/4885EGFR 4304/4885 |
| US-20110172294-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | POLM, POLRMT, HNRNPM | NPC1 2502/4885SLC9A1 4880/4885EGFR 4316/4885 |
| US-20140073786-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | POLM, POLRMT, HNRNPM | NPC1 1812/4885SLC9A1 4872/4885EGFR 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.